PROQR THERAPEUTICS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.02 USD | +1.00% |
|
+1.00% | +2.02% |
Financials (USD)
| Sales 2024 * | 20.8M | Sales 2025 * | 19.22M | Capitalization | 164M |
|---|---|---|---|---|---|
| Net income 2024 * | -39M | Net income 2025 * | -34M | EV / Sales 2024 * | 7.9 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 8.55 x |
| P/E ratio 2024 * |
-4.54
x | P/E ratio 2025 * |
-4.93
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on ProQR Therapeutics N.V.
More recommendations
More press releases
More news
| 1 day | +1.00% | ||
| 1 week | +1.00% | ||
| Current month | -11.79% | ||
| 1 month | -15.13% | ||
| 3 months | +0.50% | ||
| 6 months | +64.23% | ||
| Current year | +2.02% |
1 week
1.81
2.12
1 month
1.812.49
Current year
1.703.29
1 year
1.113.29
3 years
0.539.09
5 years
0.5313.28
10 years
0.5327.60
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel de Boer
CEO | Chief Executive Officer | 41 | 12-02-20 |
| Founder | 60 | 12-02-20 | |
Jurriaan Dekkers
DFI | Director of Finance/CFO | - | 22-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Domenico Valerio
FOU | Founder | 67 | 12-02-20 |
| Founder | 60 | 12-02-20 | |
Alison Lawton
BRD | Director/Board Member | 62 | 14-09-16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 2.02 | +1.00% | 185,505 |
| 24-04-22 | 2 | +0.50% | 113,304 |
| 24-04-19 | 1.99 | +6.99% | 134,020 |
| 24-04-18 | 1.86 | -2.11% | 182,726 |
| 24-04-17 | 1.9 | -5.00% | 197,899 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leberâs congenital amaurosis (LCA).
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2
USD
Average target price
4.1
USD
Spread / Average Target
+105.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.02% | 164M | |
| -0.49% | 105B | |
| +3.31% | 97.5B | |
| +1.66% | 22.19B | |
| -16.16% | 21.33B | |
| -6.82% | 18.68B | |
| -41.41% | 16.6B | |
| -22.87% | 14.52B | |
| +6.32% | 14.09B | |
| +21.46% | 10.99B |
- Stock Market
- Equities
- PRQR Stock
